TMT101 for advanced pancreatic or lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced pancreatic cancer or non-small cell lung cancer that has not responded to or stopped working with at least two prior treatments for pancreatic cancer, or platinum chemo and immunotherapy for lung cancer.
- You must have at least one tumor that can be measured on scans.
- You must be well enough to carry out daily activities (ECOG score 0 or 1).
- Your organs (kidneys, liver, blood counts) must work well enough per lab tests.
- You cannot have had certain treatments like chemotherapy or major surgery within the past 4 weeks, or have certain other health issues like uncontrolled infections or active brain tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
This trial tests a new treatment called CHT102 for people with advanced pancreatic cancer that has a specific protein (mesothelin) on their tumor cells. It's for those who have already tried standard treatments without success or couldn't tolerate them.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.